NASDAQ:DCPH

Deciphera Pharmaceuticals (DCPH) Stock Forecast, Price & News

$12.88

-0.37 (-2.79%)

(As of 09/22/2023 ET)

Compare

Today's Range: $12.79
▼
$13.41
50-Day Range: $12.82
▼
$15.48
52-Week Range: $12.73
▼
$22.76

Volume: 273,293 shs
Average Volume: 388,506 shs
Market Capitalization: $1.02 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $22.71

Deciphera Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.63 Rating Score
Upside/Downside: 76.4% Upside
$22.71 Price Target
Short Interest: Bearish
7.82% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.35
Upright™ Environmental Score
News Sentiment: 0.84
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.36) to ($2.17) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

471st out of 963 stocks

Pharmaceutical Preparations Industry

210th out of 458 stocks

3.3

Analyst's Opinion

Consensus Rating
Deciphera Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 6 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $22.71, Deciphera Pharmaceuticals has a forecasted upside of 76.4% from its current price of $12.88.
Amount of Analyst Coverage
Deciphera Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.82% of the float of Deciphera Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Deciphera Pharmaceuticals has a short interest ratio ("days to cover") of 9.9.
Change versus previous month
Short interest in Deciphera Pharmaceuticals has recently increased by 4.17%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Deciphera Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Deciphera Pharmaceuticals does not have a long track record of dividend growth.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Deciphera Pharmaceuticals has received a 55.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Ripretinib", and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for Deciphera Pharmaceuticals is -1.35.

3.2

News and Social Media Coverage

News Sentiment
Deciphera Pharmaceuticals has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Deciphera Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
9 people have searched for DCPH on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Deciphera Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.43% of the stock of Deciphera Pharmaceuticals is held by insiders.
Percentage Held by Institutions
70.96% of the stock of Deciphera Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Deciphera Pharmaceuticals are expected to grow in the coming year, from ($2.36) to ($2.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Deciphera Pharmaceuticals is -5.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Deciphera Pharmaceuticals is -5.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Deciphera Pharmaceuticals has a P/B Ratio of 2.55. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Deciphera Pharmaceuticals (NASDAQ:DCPH) Stock

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

DCPH Price History

30 days | 90 days | 365 days | Advanced Chart

DCPH Stock News Headlines

September 22, 2023 | finance.yahoo.com

Deciphera Pharmaceuticals (DCPH): An Intriguing Value Play with a Modestly Undervalued Market ...

September 22, 2023 | finance.yahoo.com

Deciphera Pharmaceuticals Inc (DCPH): A Deep Dive into Its Performance Potential

September 24, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

August 22, 2023 | finance.yahoo.com

Deciphera Pharmaceuticals (NASDAQ:DCPH) shareholders have endured a 66% loss from investing in the stock three years ago

August 22, 2023 | seekingalpha.com

Deciphera Pharmaceuticals: Clawing Its Way Back

August 11, 2023 | finance.yahoo.com

Why Shares of Deciphera Pharmaceuticals Rose This Week

August 11, 2023 | msn.com

Stifel Upgrades Deciphera Pharmaceuticals (DCPH)

August 11, 2023 | msn.com

HC Wainwright & Co. Reiterates Deciphera Pharmaceuticals (DCPH) Buy Recommendation

September 24, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

August 10, 2023 | markets.businessinsider.com

Barclays Sticks to Their Sell Rating for Deciphera Pharmaceuticals (DCPH)

August 10, 2023 | markets.businessinsider.com

JMP Securities Keeps Their Buy Rating on Deciphera Pharmaceuticals (DCPH)

August 8, 2023 | benzinga.com

Earnings Preview: Deciphera Pharmaceuticals

August 4, 2023 | finance.yahoo.com

DCPH - Deciphera Pharmaceuticals, Inc.

August 3, 2023 | finance.yahoo.com

Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer

August 2, 2023 | finance.yahoo.com

Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023

June 18, 2023 | seekingalpha.com

Deciphera Is A Buy In Expectation Of A Significant Comeback

June 9, 2023 | finance.yahoo.com

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

June 5, 2023 | msn.com

JMP Securities Reiterates Deciphera Pharmaceuticals (DCPH) Market Outperform Recommendation

May 8, 2023 | markets.businessinsider.com

JonesTrading Remains a Hold on Deciphera Pharmaceuticals (DCPH)

May 7, 2023 | seekingalpha.com

Deciphera Pharmaceuticals, Inc. (DCPH) Q1 2023 Earnings Call Transcript

May 5, 2023 | benzinga.com

Deciphera Pharmaceuticals Stock (NASDAQ:DCPH), Dividends

May 3, 2023 | finance.yahoo.com

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Lags Revenue Estimates

May 3, 2023 | msn.com

Recap: Deciphera Pharmaceuticals Q1 Earnings

May 3, 2023 | finance.yahoo.com

Deciphera Pharmaceuticals Announces First Quarter 2023 Financial Results

May 2, 2023 | markets.businessinsider.com

What Wall Street expects from Deciphera Pharmaceuticals's earnings

April 26, 2023 | finance.yahoo.com

Will Deciphera Pharmaceuticals, Inc. (DCPH) Report Negative Q1 Earnings? What You Should Know

April 26, 2023 | finance.yahoo.com

Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023

See More Headlines

Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DCPH Company Calendar

Last Earnings: 8/09/2023
Today: 9/24/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DCPH
CUSIP: N/A
CIK: 1654151
Web: www.deciphera.com
Phone: (781) 209-6400
Fax: N/A
Employees: 300
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $22.71
High Stock Price Forecast: $30.00
Low Stock Price Forecast: $9.00
Forecasted Upside/Downside: +76.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.63
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-178,930,000.00
Net Margins: -129.90%
Pretax Margin: -129.40%
Return on Equity: -47.99%
Return on Assets: -37.64%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.00
Quick Ratio: 4.69

Sales & Book Value

Annual Sales: $144.07 million
Price / Sales: 7.05
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.05 per share
Price / Book: 2.55

Miscellaneous

Outstanding Shares: 78,821,000
Free Float: 75,329,000
Market Cap: $1.02 billion
Optionable: Optionable
Beta: 0.69

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Steven L. Hoerter (Age 52)
Pres, CEO & Director
Comp: $1.24M

Dr. Daniel L. Flynn Ph.D. (Age 68)
Exec. VP, Chief Scientific Officer & Founder
Comp: $759.18k

Mr. Thomas Patrick Kelly J.D. (Age 52)
Exec. VP, CFO & Treasurer
Comp: $778.85k

Mr. Daniel C. Martin (Age 48)
Sr. VP & Chief Commercial Officer
Comp: $711.42k

Dr. Matthew L. Sherman M.D. (Age 67)
Exec. VP & Chief Medical Officer
Comp: $865.62k

Dr. Kevin Brodbeck Ph.D.
Sr. VP & Chief Technical Officer

Jennifer Larson
Sr. VP of Fin. & Investor Relations

Mr. Jeffrey M. Held J.D.
Sr. VP & Gen. Counsel

Ms. Lisa Amaya Price
Sr. VP & Chief HR Officer

Ms. Jama Pitman (Age 44)
Sr. VP of Regulatory, Quality & Portfolio Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DCPH Stock - Frequently Asked Questions

Should I buy or sell Deciphera Pharmaceuticals stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DCPH shares.
View DCPH analyst ratings or view top-rated stocks.
What is Deciphera Pharmaceuticals' stock price forecast for 2023?: 8 equities research analysts have issued 1 year price targets for Deciphera Pharmaceuticals' stock. Their DCPH share price forecasts range from $9.00 to $30.00. On average, they expect the company's stock price to reach $22.71 in the next twelve months. This suggests a possible upside of 76.4% from the stock's current price.
View analysts price targets for DCPH or view top-rated stocks among Wall Street analysts.
How have DCPH shares performed in 2023?: Deciphera Pharmaceuticals' stock was trading at $16.39 at the beginning of 2023. Since then, DCPH shares have decreased by 21.4% and is now trading at $12.88.
View the best growth stocks for 2023 here.
When is Deciphera Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our DCPH earnings forecast.
How were Deciphera Pharmaceuticals' earnings last quarter?: Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) issued its earnings results on Wednesday, August, 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.05. The firm earned $38.30 million during the quarter, compared to analysts' expectations of $36.09 million. Deciphera Pharmaceuticals had a negative trailing twelve-month return on equity of 47.99% and a negative net margin of 129.90%. The firm's revenue was up 17.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.60) EPS.
What ETFs hold Deciphera Pharmaceuticals' stock?: ETFs with the largest weight of Deciphera Pharmaceuticals (NASDAQ:DCPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).Range Cancer Therapeutics ETF (CNCR).
What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?: 3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Deciphera Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

When did Deciphera Pharmaceuticals IPO?: (DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.
What is Deciphera Pharmaceuticals' stock symbol?: Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."
Who are Deciphera Pharmaceuticals' major shareholders?: Deciphera Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.96%), Braidwell LP (4.63%), State Street Corp (4.02%), Goldman Sachs Group Inc. (2.69%), Dimensional Fund Advisors LP (1.79%) and Nuveen Asset Management LLC (1.72%). Insiders that own company stock include Brightstar Associates Llc, Daniel C Martin, Daniel Lee Flynn, Dennis Leo Walsh, Franklin Stuart Friedman, Jama Pitman, James Arthur Bristol, Matthew L Sherman, Michael Douglas Taylor, Steven L Hoerter and Thomas Patrick Kelly.
View institutional ownership trends.
How do I buy shares of Deciphera Pharmaceuticals?: Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Deciphera Pharmaceuticals' stock price today?: One share of DCPH stock can currently be purchased for approximately $12.88.
How much money does Deciphera Pharmaceuticals make?: Deciphera Pharmaceuticals (NASDAQ:DCPH) has a market capitalization of $1.02 billion and generates $144.07 million in revenue each year. The company earns $-178,930,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis.
How many employees does Deciphera Pharmaceuticals have?: The company employs 300 workers across the globe.
How can I contact Deciphera Pharmaceuticals?: Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The official website for the company is www.deciphera.com. The company can be reached via phone at (781) 209-6400 or via email at eciphera@argotpartners.com.

This page (NASDAQ:DCPH) was last updated on 9/24/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial